Ampio Pharmaceuticals, Inc., a developer of innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease, recently announced that the company has initiated a Phase II clinical trial of Optina™ for the treatment of diabetic macular edema, an early stage of diabetic retinopathy.

Vision loss, diabetic macular edema and diabetic retinopathy are complications of diabetes mellitus that occur in roughly one third of patients 10 years after the onset of diabetes. Optina™ is an oral drug with an established human safety profile. Pre-clinical studies have shown the potential for Optina™ to significantly reduce diabetic macular edema in patients. Ampio Pharmaceuticals has completed a formal agreement with St Michael’s Hospital, Toronto, Canada as a final step for ethics board approval, which is expected in the next few days.

Don Wingerter, chief executive officer of Ampio Pharmaceuticals, stated, “We are very excited to be commencing this trial and pending the final approval of the ethics board we will commence patient recruitment in the next weeks.”

Chief Scientific Officer, Dr. David Bar-Or added, “After accumulating in vitro and animal data, it is gratifying to begin treating patients for this debilitating disease.”

For more information, please visit www.ampiopharma.com.